David Owens, boss Medical (Tase 🙂 Officer Nexalin technology Inch. (Nasdaq :), reported to buy usual shares worth $ 7,700. Time has been observed because the shares have experienced significant volatility, almost 18% fell in last week, despite an impressive 607% gain last year. Transactions occurred on January 13th and 2nd, and Owens acquired a total of 3,000 shares. The shares were purchased at prices ranging from $ 2.50 to $ 2,70 per share, below the current shopping price of $ 2.72. After these acquisitions, Owens holds 152,293 shares directly in a companies with a market cap of $ 33.4 million. These transactions highlight Owens’s constant investment in the company, which states the proper result of financial health according to Investmentwhich offers 11 additional investment investments for this section.
In other recent news, Nexalin Technology, Inc. She regained the compliance with Nasdaq’s request for a minimum offer, which is a significant turning point for Mark White, the company’s executive. This development increases the visibility of the investor as Nexalin continues its clinical research and global regulatory approval. The company also successfully fulfilled the requirements of the shareholder’s shareholder’s shares after a public offer that raised about $ 5.25 million.
In the Committee news newspapers, five directors were selected at a recent annual shareholder meeting, which is also a ratification of Marcum LLP for the coming fiscal year, an independent registered public accounting company was recorded. However, the company announced the departure of Michael Nketiah, a higher vice -president of clinical, quality and regulatory affairs.
In the field of product development, Nexalin has achieved progress with his neurostimulation device Gen-2 15 Miliamp, who recently received approval in Oman and China. These are the latest events in the liquid business Nexalin Technology. The company has not committed to update these statements forward after the date of publicity announcement unless legally needed.
This article was generated with the support of AI and was examined by the editor. See our T&C for more information.
